Status:

ACTIVE_NOT_RECRUITING

Understanding and Testing Recovery Processes for PTSD and Alcohol Use Following Sexual Assault

Lead Sponsor:

University of Washington

Collaborating Sponsors:

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Conditions:

Alcohol; Use, Problem

Posttraumatic Stress Disorder

Eligibility:

FEMALE

18-65 years

Phase:

NA

Brief Summary

Sexual assault can lead to devastating consequences including the development of chronic conditions including posttraumatic stress disorder (PTSD) and alcohol use disorders (AUD). Interventions delive...

Detailed Description

Following sexual assault, many individuals will develop chronic problems including posttraumatic stress disorder (PTSD) and alcohol use disorders (AUD). Intervention provided soon after assault can de...

Eligibility Criteria

Inclusion

  • Identifies as female.
  • Between the age of 18 and 65.
  • Reports a sexual assault in the last 4 weeks to 1 year.
  • Current PTSD severity of 23+ on the PSS-I-5.
  • Current heavy alcohol use (2+ heavy episodic drinking occasions \[4+ drinks on one occasion\] in past month).
  • Access to the internet and a device with a webcam.

Exclusion

  • Current diagnosis of schizophrenia, delusional disorder, or organic mental disorder as defined by the DSM-5.
  • Current diagnosis of bipolar disorder, depression with psychotic features, or depression severe enough to require immediate psychiatric treatment (i.e., serious suicide risk with intent and plan).
  • Unwilling or unable to discontinue current trauma-focused psychotherapy or current substance use psychotherapy.
  • Unstable dose of psychotropic medications in the prior 3 months.
  • Ongoing intimate relationship with the perpetrator of most recent assault.
  • Current diagnosis of a severe substance use disorder according to DSM-5, other than alcohol in the last month.
  • No clear trauma memory.
  • Current higher dose use of benzodiazepines (greater than the equivalent of 4 mg of lorazepam, 2 mg alprazolam, 1.5 mg clonazepam, or 20 mg of diazepam).

Key Trial Info

Start Date :

June 2 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 31 2026

Estimated Enrollment :

82 Patients enrolled

Trial Details

Trial ID

NCT04124380

Start Date

June 2 2021

End Date

August 31 2026

Last Update

December 18 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Washington

Seattle, Washington, United States, 98105